---
title: "Innovent Biologics (IVBXF) Gets a Buy from SPDB"
description: "SPDB analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$110.00.Valentine's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for sma"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275968964.md"
published_at: "2026-02-14T05:06:39.000Z"
---

# Innovent Biologics (IVBXF) Gets a Buy from SPDB

> SPDB analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$110.00.Valentine's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential In addition to SPDB, Innovent Biologics also received a Buy from Bernstein’s Rebecca Liang in a report issued on February 9. However, on February 4, TipRanks – OpenAI reiterated a Hold rating on Innovent Biologics (Other OTC: IVBXF).

SPDB analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$110.00.

### Valentine's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

In addition to SPDB, Innovent Biologics also received a Buy from Bernstein’s Rebecca Liang in a report issued on February 9. However, on February 4, TipRanks – OpenAI reiterated a Hold rating on Innovent Biologics (Other OTC: IVBXF).

### Related Stocks

- [01801.HK - INNOVENT BIO](https://longbridge.com/en/quote/01801.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts Innovent Biologics' Price Target to HK$114.64 From HK$105.08, Keeps at Buy | Nomura Adjusts Innovent Biologics' Price Target to HK$114.64 From HK$105.08, Keeps at Buy | [Link](https://longbridge.com/en/news/275882948.md) |
| China's Innovent clinches new Lilly deal for immunology, cancer drug development | China’s Innovent Biologics has secured a new deal with Eli Lilly for the development of immunology and oncology drugs, i | [Link](https://longbridge.com/en/news/275255059.md) |
| Innovent Biologics' Q4 Revenue Surges 60% | Innovent Biologics' Q4 Revenue Surges 60% | [Link](https://longbridge.com/en/news/274820825.md) |
| Innovent Bio's Tabosun Gets China Nod as Pre-treatment for Colon Cancer | Innovent Bio's Tabosun Gets China Nod as Pre-treatment for Colon Cancer | [Link](https://longbridge.com/en/news/270943961.md) |
| Innovent Biologics: Rising Star in Biopharma | Innovent Biologics is emerging as a leader in China's biopharma sector, shifting from generics to innovative biopharmace | [Link](https://longbridge.com/en/news/272238000.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.